Therapy Detail

Therapy Name Cetuximab + lenalidomide
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cetuximab Erbitux EGFR Antibody 27 Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).
Lenalidomide Revlimid IMiD-1 Revlimid (lenalidomide) inhibits angiogenesis and promotes G1 cell cycle arrest and apoptosis of malignant cells. It is a thalidomide analog which inhibits TNF-alpha production, stimulates T cells, and reduces serum levels of the cytokines VEGF and bFGF (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS wild-type head and neck squamous cell carcinoma predicted - sensitive Cetuximab + lenalidomide Phase I Actionable In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in stable disease in 67% (2/3) of KRAS wild-type head and neck squamous cell cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141). 27458141
KRAS wild-type colorectal cancer predicted - sensitive Cetuximab + lenalidomide Phase I Actionable In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in partial response in 5% (1/19) and stable disease in 32% (6/19) of KRAS wild-type colorectal cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141). 27458141
Clinical Trial Phase Therapies Title Recruitment Status